A clinical trial update dated October 16, 2026 reports on a study titled "Psychological Support for Chronic Migraine Patients Treated With Anti-CGRP (Anti-Calcitonin Gene-Related Peptide) Monoclonal Antibodies." The study, registered as NCT07877493, is listed with a status of not yet recruiting. No phase is specified for this trial in the available record. The trial focuses on chronic migraine patients who are being treated with anti-CGRP monoclonal antibodies, a drug class related to calcitonin gene-related peptide signaling. Calcitonin itself remains an approved compound used in various clinical contexts. As the study has not yet begun recruiting participants, no enrollment numbers, outcomes, or results are currently available. Updates on recruitment status and any future results would be reflected in subsequent registry entries for this trial identifier. Readers interested in this trial can track its progress through its official clinical trial registry listing. For additional background on calcitonin as a compound, readers can consult the compound overview.
Trial Update: Anti-CGRP Antibody Study in Migraine Patients Not Yet Recruiting
See the full calcitonin overview
Source: https://clinicaltrials.gov/study/NCT07877493